4 completed, 1 unknown. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Unknown 1 |
Follow Wuhan Createrna Science and Technology Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function MY008211A tablets - Hepatic Insufficiency (MeSH ID: D048550) | Phase 1 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 24 | 2024-09-20 | 2026-06-04 |
| To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects MY008211A tablets, Placebo - Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Unknown | Wuhan Createrna Science and Technology Co., Ltd | 16 | 2024-08-10 | 2024-08-09 |
| A Study of Multiple Ascending Doses MY008211A in Healthy Adults MY008211A tablets, MY008211A tablets matched placebo - Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 40 | 2023-01-10 | 2023-09-08 |
| Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects MY008211A tablets - Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 12 | 2022-09-26 | 2023-04-25 |
| A Study of Single-dose MY008211A in Healthy Adults MY008211A tablets, Placebo - Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 63 | 2022-05-27 | 2023-09-08 |
Hemoglobinuria, Paroxysmal (4) · Hepatic Insufficiency (1)
China (5)
Haiyan Li, PhD (1) · YaNan Wang, PHD (1)